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Abstract
COPD is heterogeneous, and its presentation varies between countries. The major COPD cohort studies
have only been performed in Western populations; the disease is not well characterised in other regions.
The COMPASS (Investigation of the Clinical, Radiological and Biological Factors, Humanistic and
Healthcare Utilisation Burden Associated with Disease Progression, Phenotypes and Endotypes of COPD
in China; NCT04853225) is a prospective, 2.5-year-long, multi-centre, longitudinal, observational study
with three aims: 1) to characterise stable and exacerbation phenotypes/endotypes in terms of clinical
characteristics, blood and sputum biomarkers, lung microbiome and lung imaging; 2) to understand the
relevance of markers of COPD disease progression identified in Western cohorts to Chinese patients; and
3) to characterise treatment pathways and healthcare resource utilisation. COMPASS will recruit 2000
participants, of which 1700 will be in Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Grades I–IV (n=700, 700, 200 and 100, respectively), 180 participants with chronic bronchitis without
airflow limitation and 120 never-smoker healthy controls. Study visits will be at baseline, 6, 18 and
30 months and at exacerbation. Assessments include lung function, exacerbation frequency, health status,
blood biomarkers and, in a sub-cohort of 400 patients, chest high-resolution computed tomography,
additional blood and sputum biomarkers, airway micro-, viral- and myco-biome, and physical activity.
COMPASS will establish a unique clinical and biological dataset in a well-characterised cohort of
individuals with COPD in China, with a particular focus on milder patients. As the first study of its kind
attempting to understand the disease in an Asian setting, it will provide valuable insights into regional and
ethnic differences in COPD.
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Introduction
COPD is one of the leading causes of morbidity and mortality resulting in significant humanistic and
economic burden to patients, healthcare systems and societies worldwide. It is the third leading cause of
death globally, and in 2019 there were 3.23 million deaths due to COPD [1]. COPD prevalence in China
has been increasing significantly. A national screening survey, conducted from 2002 to 2004, reported that
the overall prevalence of spirometry-defined COPD among people over 40 years old was 8.2% [2]. The
recently published China Pulmonary Health Study (2018) suggested that the prevalence of COPD among
Chinese over 40 years old had increased to 13.7% [3]. Although COPD management in China has greatly
improved over the past decades, many challenges persist. One of them is a substantial under-diagnosis: in
a 2007 study, up to 65% of people with airflow limitation pattern compatible with COPD did not have a
clinical diagnosis of COPD [2]. Furthermore, most individuals diagnosed with COPD (64.7%) exhibited a
significant symptom burden, defined as at least one respiratory symptom (cough, phlegm, wheezing and
breathlessness), regardless of treatment [2]. Its health status impact, as judged by COPD Assessment Test
(CAT) score, also appears to be higher in China than in the West. In one study of over 6000 patients across
China, the mean score was 24, compared to under 20 commonly reported in Europe [4].
COPD is a heterogeneous and complex condition displaying a range of phenotypes and endotypes with
distinct underlying mechanisms, different clinical outcomes, varying patterns of progression, prognostic
characteristics and different responses to treatment. The heterogeneity reflects the fact that not all COPD
components are present in all patients and the complexity is due to dynamic and nonlinear interactions
between the components that are present [5]. This indicates the need for personalised management, for
example using a treatable traits approach to assessment, classification and management of COPD [6, 7].
Three large observational studies – Evaluation of COPD Longitudinally to Identify Predictive Surrogate
End-points (ECLIPSE) [8], Genetic Epidemiology of COPD (COPDGene) Study [9], and Subpopulations
and Intermediate Outcomes in COPD Study (SPIROMICS) [10] – were designed to address the complexity
and heterogeneity of COPD, but they were all conducted in North America and Europe. A fourth study in
individuals with obstructive lung disease (NOVELTY) is ongoing and includes patients in Asia. In contrast
to the other three studies, it includes individuals with asthma as well as COPD, but does not have the same
comprehensive range of in-depth assessment [11] (e.g. sputum biomarkers). The absence of studies in Asia
is a limitation, not only locally within the region, but also globally in terms of understanding the full
picture of the disease. For example, lung growth as measured by forced vital capacity (FVC) is related to a
country’s gross national income per capita [12], which is important with the increasing recognition that
failure of full lung growth in childhood and early adulthood is a cause of COPD [13]. In addition, there
may be substantial differences between countries in different continents in terms of respiratory symptoms
and comorbid respiratory conditions [14], since significant racial differences have been reported between
Korea and the USA in the pattern of extrapulmonary comorbidities [15]. Age-standardised
disability-adjusted life years due to COPD vary quite widely between the USA and China and even within
Europe [16]. Pollution is an important factor in COPD, and, setting aside the well-known effects of
industrial pollution, levels of death due to indoor air pollution are much higher in China and Asia than in
Europe and the USA [17]. Taken together with high levels of biomass fuel exposure for a significant part
of the lives of currently middle-aged people before the relatively recent mass urbanisation that has taken
place in China, these factors may result in a higher proportion of non-cigarette-smoking-related COPD.
COPD patients in China show significant differences when compared with Western patients. In the Asian
cohort study [18] of the Tiotropium Safety and Performance In Respimat (TIOSPIR) trial [19], ZHONG
et al. [18] demonstrated that Asian COPD patients had significantly lower body mass index (BMI), had a
higher proportion of males, less cardiovascular disease and fewer but more severe exacerbations than those
in the West. With an ageing population, persistent air pollution and significant biomass fuel exposure in
China, the humanistic and economic burden of COPD is expected to increase and will require more
healthcare resources in the future. COPD has been identified as a key disease of focus, and its appropriate
management is a healthcare priority in China. To inform clinical practice and aid public health resource
allocation, it is important to gain a better understanding of disease progression and clinical management of
COPD in China. In particular it is important to understand the characteristics of the disease earlier in the
evolution of the disease and in patients with milder airflow limitation, because this is where
disease-modifying strategies will have greatest long-term benefit.
The COMPASS study (GlaxoSmithKline study Number 208630, ClinicalTrials.gov identifier:
NCT04853225) is a 2.5-year longitudinal study with the overall objective of expanding understanding of
the pattern of COPD disease phenotypes/endotypes, clinical, humanistic, and healthcare utilisation burden,
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disease progression and management of COPD in China, especially in patients with mild-to-moderate
COPD. This article describes the purpose, design and objectives of this study.
Methods
Study objective
The key objectives of COMPASS are to: 1) characterise stable disease and exacerbation phenotypes/
endotypes in China through assessment of clinical characteristics, blood biomarkers, lung microbiome and
radiological features of COPD; 2) understand the relevance of predictors of COPD disease progression
identified in Western cohorts to Chinese patients; 3) characterise treatment pathways and healthcare
resource utilisation and costs in COPD; 4) explore the utility of integrated digital data collected from
multiple sources in the assessment and management of COPD patients.
Study design
COMPASS is a prospective, longitudinal 2.5-year multi-centre, non-drug interventional, observational
study being conducted at 41 centres in Guangdong and Fujian, China. It will enrol 2000 participants into
three strata (never-smoker healthy participants, chronic bronchitis without airflow limitation and COPD
current or former smokers or never-smokers) as shown in figure 1. A sub-cohort with 400 participants will
be studied in greater detail (figure 1).
Study participants
Inclusion criteria are participants must be 40–80 years of age at baseline for the main cohort, have a
smoking history of <1 pack-year (for never-smoking COPD participants, chronic bronchitis and healthy
participants) or ⩾1 pack-year (smoking and ex-smoking COPD and chronic bronchitis) and meet lung
function criteria as specified in table 1. Major exclusion criteria are respiratory disorders other than COPD
(e.g. lung cancer, sarcoidosis, active tuberculosis, lung fibrosis, severe bronchiectasis, cystic fibrosis and
alpha-1 antitrypsin deficiency). A current primary diagnosis of asthma is an exclusion criterion but
individuals with a primary diagnosis of COPD but who also have had asthma can be included. Previous
major lung surgery (e.g. lobectomy, lung reduction, lung transplant) is an exclusion criterion, as is a
diagnosis of any cancer: current and within the last 5 years (patients in remission for ⩾5 years could be
included). Table 1 contains the inclusion criteria. An exacerbation is defined as the occurrence of an
episode of increased cough (with or without phlegm), shortness of breath or chest symptoms (chest
discomfort or tightness) which lasted 48 h or more and interfered with the subject’s usual activities. It is
based on a definition used in the BOLD and CANCOLD surveys that also included mild patients [20, 21]
To minimise the risk of ionising radiation as a consequence of repeated exposure to low-dose computed
tomography scans of the chest, a minimum age of 50 years was selected for the sub-cohort. The study was
approved by the ethics committee of each research centre and Human Genetic Resource Administration of
China (HGRAC).
Baseline and follow-up assessments
There will be four on-site visits – baseline, 6 months, 18 months and 30 months – to collect concurrent
medications, smoking status, spirometry, CAT score, healthcare resource utilisation/cost, etc. Participants
will also receive trimonthly follow-up calls to assess CAT score, medication/treatment and exacerbation
events. At baseline and 30 months biomarkers including the following will be collected: fibrinogen [22]/
high-sensitivity C-reactive protein (hsCRP)/blood cell count and blood biomarkers (inclusive of serum
sRAGE, CC16, HbA1c and IP-10; sub-cohort only). In the sub-cohort, sputum cytology, sputum
microbiome and chest high-resolution computed tomography (HRCT) scan (at maximum inspiration and
expiration) will be performed.
Outcome measurements
End-points measured in COMPASS include rate of decline in forced expiratory volume in 1 s (FEV1), rate
of moderate/severe exacerbations, change in health status scores over time, clinically important
deterioration composite outcome, rate of decline in lung density change from baseline in airway diameter
(quantified by HRCT; sub-cohort only), mortality and blood biomarker, etc. The key end-points are listed
in figure 2.
Airway micro-, viral- and myco-biome
The airway microbial community (microbiome) is a complex mixture of organisms [23]. In COPD, airway
microbial dysbiosis (change in microbiome diversity and composition) is associated with disease severity
and exacerbations [24–26]. Such studies have almost exclusively assessed patients in North America and
Europe. Although studies of airway microbiome are now being performed in Asia [15], there is very
limited information on the composition of the airway microbiome and host–microbiome interactions in
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Asian patients with chronic respiratory diseases. It is plausible that, given differences in genetics,
environment and lifestyle, the airway microbiome in Asia may differ from that observed in Western
cohorts. In the COMPASS digital and biomarker subgroup, in addition to in-depth clinical and biomarker
profiling we will conduct a detailed analysis using induced or spontaneous sputum samples to analyse the
bacterial, viral and fungal components of the airway microbiome. Sputum samples are more easily
obtainable than bronchoalveolar lavage samples, and studies have shown that sputum has utility in
assessing the abundance of microbiota and that sputum microbiome alterations correlate with clinical
outcomes [27]. These sputum samples will be collected at baseline, at the last visit (Month 30 or early
withdrawal visit) and following a visit for an exacerbation. This will be one of the largest studies of the
airway microbiome to date.
Sample size considerations
This study is exploratory with no formal pre-specified hypotheses associated with the study objectives.
Confidence intervals will accompany all effects estimates. Sample size justification is based on precision
(half width of confidence interval) for the difference between the rates of decline in FEV1 of Global
Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and GOLD 2 subjects over 2.5 years. Under the
foregoing assumptions, with 95% confidence interval and a 25% drop out, ∼700 subjects for each group
Entire cohort, n=2000
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FIGURE 1 COMPASS enrolment strata. Type A hospitals include all hospitals at prefecture level or higher; Type B hospitals include all hospitals
below the prefecture level, including community hospitals. #: chronic bronchitis defined by at least 3 months of cough and phlegm in a year in the
past 2 years and normal spirometry. ¶: never-smokers are defined as a lifetime exposure of <1 pack-year. +: exacerbator is a patient who has one or
more exacerbations in the 2 years before recruitment (see text). §: non-exacerbator is defined as a patient who has not had an exacerbation in the
2 years before entry into the study. ƒ: inhaled maintenance treatment naïve patients are defined as not being treated in at least prior 12 months
with any long-acting inhaled medications inclusive of inhaled corticosteroids, long-acting antimuscarinic or long-acting β2-agonists. GOLD: Global
Initiative for Chronic Obstructive Lung Disease.
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(GOLD 1 and GOLD 2) should be enrolled to maintain a precision (half width of confidence interval) of
no more than 15 mL·year−1 for the difference between the rates of decline in FEV1 of GOLD 1 to GOLD
2 subjects. Within each GOLD group and the chronic bronchitis group, a recruitment target of 15–30% of
never-smokers has been set.







Inclusion criteria (all the following criteria apply)
Aged 50–80 years inclusive ✓ ✓ ✓
Baseline (post-bronchodilator) FEV1/FVC ratio <70% ⩾70% ⩾70%
CAT score <10 ✓
BMI <35 (for CT scanning reasons) ✓ ✓ ✓
Chronic mucus hypersecretion (⩾3 months of
cough and phlegm in a year in the past 2 years)
✓
No exacerbations for ⩾1 month prior to
recruitment
✓ ✓
Ever-smoker (lifetime exposure of ⩾1 pack-year) or
never-smoker (lifetime exposure of <1 pack-year)
(for healthy participants, ever-smokers and passive
smokers are not eligible)
✓ ✓ ✓
Additional criteria for sub-cohort of COPD participants
150 COPD participants with ⩾1 moderate or severe
exacerbation event within the past 2 years
✓ N/A N/A
60 COPD participants without inhaler maintenance
treatment history for ⩾12 months prior to the
entry of the study
✓ N/A N/A
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; CAT: COPD Assessment Test; BMI: body mass index.
All participants:
Sub-cohort participants:
1. Spirometry (pre- and 
 post-bronchodilator)
2. COPD exacerbation 
 assessment
3. COPD medication and 
 treatment patterns
4. HRQoL CAT (digital 
 trimonthly assessment)
5. Clinically important 
 deterioration (CID)
1. Lung HRCT 




1. Blood test: plasma 
 fibrinogen and hsCRP, 
 total and differential 
 blood cell count
1. Blood biomarkers
 (including serum sRAGE,
 CC16, IP-10, HbA1c)
2. Sputum microbiome – 
 bacteriome, virome,
 mycobiome
3. Sputum cytology – 







 outcomes: CAT, 
 SGRQ-C, mMRC 
 and Capture
3. Healthcare 
 resource utilisation 
1. Exacerbations of 
 Chronic Pulmonary 
 Disease Tool (EXACT) 
2. Evaluating Respiratory 
 Symptoms in COPD 
 (E-RS: COPD)
3. Digital daily diary
Health economics
and outcomes
FIGURE 2 COMPASS Study end-points overview. HRQoL: health-related quality of life; CAT: COPD Assessment Test;
HRCT: high-resolution computed tomography; hsCRP: high-sensitivity C-reactive protein; SGRQ-C: St George’s
Respiratory Questionnaire, COPD-specific version; mMRC: Modified Medical Research Council Dyspnoea Scale.
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Study organisation
The COMPASS study is guided by a steering committee, consisting of academic senior investigators and
representatives from the study sponsor (GlaxoSmithKline) (see figure 3). The recruiting sites are made up
of a network of 25 Tier 3 university hospitals and 15 Tier 2 general hospitals. A number of Working
Groups (WGs) will be established to cover different areas of research: e.g. imaging, microbiome,
biomarker, spirometry, etc. Each will have a lead who may or may not come from the steering committee,
and the membership will be comprised of senior and junior researchers. Overseas experts will be invited to
join the WGs, as appropriate. Each WG will determine the scientific questions to be addressed in their
area, specify the analyses to be done and write the papers. GlaxoSmithKline will provide operational and
statistical support to the WGs. A hive structure is proposed in which the WGs also interact with each other
to share insights and expertise.
Discussion
COMPASS has been designed to study the heterogeneity and complexity of COPD in China, building on
disease understanding that has come from previous cohort studies in the West. It will support longitudinal
analysis of a moderate sample size in terms of lung function and symptom progression measures which,
together with a biomarker and digital subgroup, will provide in-depth data collected using HRCT, diary
cards, activity monitors and biomarkers in blood and sputum. To ensure an adequate balance of different
phenotypes, a key feature (and a significant recruitment challenge) is the establishment of specific
recruitment targets for each clinical subgroup. The focus will be primarily on individuals with mild–
moderate airflow limitation with specific targets for participants who may have different aetiologies and
disease patterns; for example, never-smokers, individuals with mild airflow limitation but a history of
exacerbations and treatment naïve individuals who had not been taking regular maintenance treatment
before entry into the study.
COMPASS will allow us to test whether the phenotypes and endotypes seen in China follow patterns
identified in Western cohorts. Whilst it is likely that no new types of COPD will be identified, their
contribution may differ due to factors such as genetics, prior chest disease and environmental factors. The
study will also focus recruitment on more defined populations than its predecessors, particularly patients
with mild airflow limitation and never-smokers, so it may include unique features that will extend our
understanding of COPD more generally. As aforementioned, COMPASS will recruit a high proportion of
participants (70%) with milder COPD (GOLD 1–2) at baseline. These subjects will provide the


























FIGURE 3 COMPASS Research network and the organisation of steering. The steering committee is made up of
experts from GlaxoSmithKline (GSK), Guangzhou Institute of Respiratory Health (GIRH) and other senior
Chinese universities. The Working Groups (WGs) will each have their own lead who will work closely with the
steering committee. The number of WGs is illustrative. A hive structure is planned in which WGs will interact
with each other as well as with the steering committee.
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opportunity to investigate the lung function trajectories and disease progression patterns in mild–moderate
COPD yielding insights and evidence for early intervention. Unlike the GOLD 3 and 4 COPD population,
the GOLD 1 and 2 patients are a population that has not been well studied global wide due to the
difficulties in identification and recruitment. More than 70% of patients with mild COPD have a low level
of clinical symptoms which do not get the attention of the patients themselves or their doctors. Effective
diagnosis in this population depends on the identification of risk factors and case-finding for spirometry,
so few of them get detected and start intervention at a mild stage. However, lung function declines rapidly
in these patients, and damage to the small airways is evident [28–30]. A previous study found that lung
function of patients with GOLD Grade 2 declines more rapidly than patients with Grades 3 and 4, but few
data are available for Grade 1 disease [31]. The recruitment to COMPASS is being carried out in a range
of hospital types, not just university hospitals, because in China, patients are free to select their hospital
and may triage themselves to higher grade hospitals if they have more symptoms. A further factor that
should support COMPASS recruiting milder patients is that in recent years, with continuous investment
and increasing attention from the Chinese government, the management of COPD in China is shifting from
disease treatment to a focus on public health. This should create a good environment for the recruitment of
COPD patients at an early stage in their disease, and it is a hope that COMPASS will help inform an early
intervention strategy for COPD in China.
To understand the relationship between patients with mild airflow limitation and those with chronic
bronchitis but normal spirometry, recruitment will include a target for people with chronic bronchitis
including those who have been never-smokers. The subgroup of COPD participants who had not
previously received maintenance treatment is primarily to allow comparison of their airway micro-, viral-
and myco-biome with participants with similar degrees of airflow limitation who have received treatment
such as long-acting bronchodilators and inhaled corticosteroids. This should also provide the opportunity
to study changes of airway microbiota in participants who may have maintenance treatment initiated during
the course of the study. From a clinical perspective, a particular feature of the protocol for the biomarker
and digital subgroup is the investigations to be carried out during an acute exacerbation that will include
HRCT, biomarker and airway microbiome analyses.
In addition to the clinical and scientific investigations, COMPASS will also investigate the feasibility of
aggregating different types of digitally acquired data including electronic health records, electronic clinical
outcome assessments and physical activity data through direct digital data capture and integration. In part,
the purpose of this is to develop systems of collecting data that permit clinical trials of treatment efficacy
and effectiveness in a setting that is closer to a real-world setting and minimise the influences and biases
that can come from close or regular contact with healthcare professionals that is not reflected in routine care.
As with previous similar cohort studies (and where possible using similar methodology), COMPASS is
designed to provide a cross-sectional comparison between well-defined groups of COPD patients and
measure disease progression. It will also integrate these data with details of healthcare resource use,
including treatment. The characterisation of defined phenotypes and endotypes (“treatable traits”) and their
stability in mild–moderate patients over time will be important for the development of new treatments and
the management of patients in the future. In that respect, a key feature of COMPASS is use of the
Exacerbations of Chronic Pulmonary Disease Tool (EXACT) diary to detect unreported exacerbations and
determine their impact on the clinical status or accelerated disease progression.
The study is conducted mainly in the Guangdong province of China. A key reason for this was the
availability of a diverse patient population to be recruited. Whilst confining the study primarily to
Guangdong may appear to be a limitation since the findings may not represent the broader Chinese patient
population, this is not a major concern. The total population of Guangdong was 104 million in the 2010
census (7.9% of the total population of China), of which 31 million were migrants from other areas of
China who had spent at least 6 months of the previous year in Guangdong. Furthermore, this province has
been growing fast in the past 15 years to become one of the biggest regions in China with a large
population of younger people.
It is important to recognise that this study is not designed to determine the epidemiology of different
COPD phenotypes in China. That is clear from the targeted recruitment strategy. Its purpose is to build on
previous cohort studies to understand the patterns of disease and disease progression in patients in an
Asian setting. Its importance is not limited to Asia, however, because understanding the heterogeneity and
complexity of COPD in different environments and in patients with different backgrounds will lead to a
greater understanding of the disease more generally and give greater insight into reasons why it is
expressed differently in different patients.
https://doi.org/10.1183/23120541.00201-2021 7
ERJ OPEN RESEARCH STUDY PROTOCOL | Z. LIANG ET AL.
In summary, COMPASS will establish a rich set of clinical and biological data on a relatively large cohort
of well-characterised individuals with COPD in China of varying degrees of severity and different
aetiologies, including patients who never smoked tobacco and may have COPD related to other factors
such as environmental exposure to pollution including biomass smoke. The study will provide unique and
detailed insight into personalised information about the pulmonary and extrapulmonary aspects of disease
progression in Chinese patients, especially those with mild–moderate airflow limitation. It holds great
promise to address the heterogeneity and complexity of multiple components in COPD.
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